Melanotan 2 mechanism of action

The cyclic alpha-MSH analogue

The history of melanocortin therapeutics describes Melanotan II as a cyclic, truncated analogue of alpha-MSH. Seven amino acids form its ring-shaped structure. Alpha-MSH is a naturally occurring signalling peptide; the synthetic analogue was designed for stronger, more persistent activity.

An agonist activates a receptor, a protein that receives a chemical signal. “Melanocortin activators” is a useful broad description, provided the receptor and experimental setting follow it. I bridle at “targeted” whenever the word suggests a cosmetic effect can be neatly isolated from the rest of the molecule’s activity.

MC1R and pigment production

At MC1R on melanocytes, the pigment-making cells, activation raises cAMP inside the cell. That signal engages PKA and CREB, increases MITF activity and drives pigment-building enzymes including tyrosinase. The process favours eumelanin and can begin without UV exposure, as described in the melanocortin therapeutic review.

The Melanotan II pilot supplies a small human observation of darker skin. The chemical analysis of increased eumelanin comes from Melanotan 1. I separate those results because a plausible pathway and a measured pigment composition answer different questions.

MC3R, MC4R and the brain

Central melanocortin activity helps explain why appetite and sexual response turn up in this literature. In the nucleus-accumbens study in male mice, direct brain delivery reduced eating and food-seeking without changing metabolic rate or producing conditioned taste aversion. The route was integral to that experiment.

In men with psychogenic erectile dysfunction, Melanotan II produced erections in 8 of 10 participants. In hormone-primed female rats, intravenous treatment increased solicitation behaviour without increasing the mating posture. These human and animal outcomes describe distinct behaviours in distinct settings.

I prize the experiment’s specificity: less food seeking while metabolic rate stayed unchanged. It gives appetite research a more interesting question than a generic claim about “boosting metabolism”. Human weight-loss effectiveness remains unestablished.

Receptor breadth and related compounds

Melanotan II is described as a non-selective melanocortin agonist. The research context identifies MC1R with pigmentation, MC4R with appetite and sexual function, MC3R with energy regulation, and MC5R with gland function. That breadth makes a tanning-only description incomplete; the historical review follows the wider therapeutic development.

Bremelanotide development used the Melanotan II scaffold to pursue sexual-function effects with reduced pigmentation activity. Afamelanotide followed the separate pigment and photoprotection programme. The human results show how different the eventual evidence became, and the reported harms explain why receptor activity deserves more than a reassuring label.